Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
Top Cited Papers
- 22 December 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (1), 293-300
- https://doi.org/10.1182/blood-2005-06-2469
Abstract
Activating mutations in the FLT3 tyrosine kinase (TK) occur in approximately 35% of patients with acute myeloid leukemia (AML). Therefore, targeting mutated FLT3 is an attractive therapeutic strategy, and early clinical trials testing FLT3 TK inhibitors (TKI) showed measurable clinical responses. Most of these responses were transient; however, in a subset of patients blast recurrence was preceded by an interval of prolonged remission. The etiology of clinical resistance to FLT3-TKI in AML is unclear but is of major significance for the development of future therapeutic strategies. We searched for mechanisms of resistance in 6 patients with AML who had relapses upon PKC412 treatment. In an index AML patient, an algorithm of analyses was applied using clinical material. In vivo and in vitro investigation of primary blasts at relapse revealed persistent TK phosphorylation of FLT3 despite sufficient PKC412 serum levels. Through additional molecular analyses, we identified a single amino acid substitution at position 676 (N676K) within the FLT3 kinase domain as the sole cause of resistance to PKC412 in this patient. Reconstitution experiments expressing the N676K mutant in 32D cells demonstrated that FLT3-ITD-N676K was sufficient to confer an intermediate level of resistance to PKC412 in vitro. These studies point out that a genetically complex malignancy such as AML may retain dependence on a single oncogenic signal.Keywords
This publication has 28 references indexed in Scilit:
- AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutationsBlood, 2005
- Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)Blood, 2005
- Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLBlood, 2004
- Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid LeukemiaLeukemia & Lymphoma, 2003
- A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemiaBlood, 2002
- Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual diseaseBlood, 2002
- Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisBlood, 2002
- Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemiaBritish Journal of Haematology, 2001
- Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignanciesBlood, 2001
- Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell linesLeukemia, 1997